Patient instruction and specific immunotherapy after severe anaphylaxis, stratified by general characteristics and reaction circumstances.

<p>SIT: Specific immunotherapy, ENT: Ear, nose and throat/Otolaryngology.</p

First time receiving prophylactic first aid drugs following severe anaphylaxis.

<p>First time receiving prophylactic first aid drugs following severe anaphylaxis.</p

Baseline characteristics and reaction circumstances of severe anaphylaxis patients treated by emergency physicians.

<p>Reported by emergency physicians in Berlin, Germany vs. self report in anaphylaxis registry.</p>*<p>comparable catchment areas, # only those initally treated by emergency physician.</p

Drugs used for emergency treatment of anaphylaxis, by cause.

<p>Only assured cases. All application routes, error bars indicate 95% confidence intervals.</p

Patients in anaphylaxis registry, first aid treatment stratified by general characteristics and reaction circumstances.

<p>Patients in anaphylaxis registry, first aid treatment stratified by general characteristics and reaction circumstances.</p

Drugs used by emergency physicians for initial treatment of anaphylaxis.

<p>Firsthand report (EPs) vs. self report (anaphylaxis registry). Parenteral application routes only. * Weighted for age, cause and severity distribution in anaphylaxis registry, Berlin catchment area.</p

Drugs used for emergency treatment of anaphylaxis, by age.

<p>Dashed lines indicate proportion of patients having received inhalation (adrenaline) or oral (antihistamine, corticoid) treatment only, error bars indicate 95% confidence intervals.</p

Circular dichroism of rBet v 1a/rBet v 1a_S112P/R145P combinations.

<p>A) Circular dichroism of defined molar ratios of rBet v 1a/rBet v 1a_S112P/R145P. 5 μM total rBet v 1a was measured with increasing fractions of rBet v 1a_S112P/R145P from 0% to 100%. Mean residual ellipticities with 95% confidence interval and statistical evaluations at wave lengths 193 nm (B), 195 nm (C), 200 nm (D), 218 nm (E), and 222 nm (F) are shown.</p

Inhibition of IgE binding to immobilized rBet v 1a.

<p>Dose-dependent inhibition of IgE binding to surface-coated rBet v 1a by rBet v 1a/rBet v 1a_S112P/R145P mixtures in the presence of increasing molar ratios of rBet v 1a_S112P/R145P in ELISA. Curves were fitted in parallel with a 4-parameter, logistic sigmoidal curve fit with same slope, lower and upper asymptote for all curves.</p

Immunoglobulin binding of rBet v 1a and rBet v 1a_S112P/R145P.

<p>Binding of IgE from sera of subjects allergic to birch pollen bound to purified (lane 14, Coomassie stain) rBet v 1a (upper panel) and rBet v 1a_S112P/R145P (lower panel) (lanes 1–10). Binding of rabbit anti-Bet v 1 IgG to the rBet v 1a proteins is shown (lane 13). A minor degradation product of rBet v 1a_S112P/R145P detected by IgG is shown (*). As controls, serum of non-allergic subject (lane 11) and buffer control (HRP-conjugated anti human IgE antibody only) (lane 12) were used.</p